newsfilter
← Latest News
GlobeNewswire·

Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib's Mechanisms of Action at the AACR Targeting RAS Conference

Data suggest rigosertib stimulates an anti-cancer immune response via NLRP3 activation, providing mechanistic support for clinical trials of rigosertib-checkpoint inhibitor combinations Data reveal potential targets